– USA, CA – Lineage Cell Therapeutics, Inc. (NYSE: LCTX | TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr. Dipti Amin, FFPM to its Board of Directors, effective on April 20, 2021.
“We are honored that Dr. Amin will be joining Lineage’s Board of Directors at this important time in the advancement of our mission to become the leading allogeneic cell transplant company,” said Board Chairman, Al Kingsley.
He added: “Dr. Amin has had leadership responsibility for many aspects of pharmaceutical product development and clinical trials and has worked with numerous sponsors on countless product candidates while at Quintiles. We believe her breadth of experience in clinical research and drug development, as well as her medical expertise and practical operational experience, will be particularly valuable to our Board and management team as Lineage continues to advance its three product candidates toward later-stage clinical trials. We look forward to her support in guiding our corporate, product, and clinical strategy as we position ourselves for years of growth in the field of cell therapy.”
About Dr. Dipti Amin
Dipti Amin is an experienced Non-Executive Director and medically trained senior executive with a passion for high-quality pharmaceutical research and healthcare, and extensive commercial, leadership, operational experience, in the private & public sectors, in medicine, pharmacology, and the highly-regulated healthcare & research sectors, as well as compliance expertise. Over a span of more than 26 years, Dr. Amin has held positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level, delivering consistently on growth, quality, customer, employee, and process targets. Her broad experience covers Clinical Pharmacology, ethical issues in clinical research, drug development, ethics, and compliance programs as well as leadership and management of large, multi-functional, multi-geography, global groups to deliver value-added, efficient growth and achieving business turnarounds. Dr. Amin has extensive international operational experience, including in the U.S., India, East Asia, and Africa.
Dr. Amin spent more than 20 years at Quintiles Transnational, the world’s largest provider of biopharmaceutical development & commercial outsourcing services. During her tenure, Dr. Amin served in several senior executive roles including Compliance; Ethics & Quality; Drug Safety and Medical Affairs; Medical and Scientific Services; Regulatory Affairs, Medical Writing and Strategic Drug Development; and Clinical Development and Scientific Operations. Dr. Amin has successfully developed strategy and helped grow the P&L, sales & management for business units generating up to $600 million in revenue while employing internationally based, multi-functional groups of highly qualified personnel. Dr. Amin is an Honorary Lecturer in Clinical Pharmacology at Guy’s, King’s, and St. Thomas’ Hospitals Medical & Dental Schools. Dr. Amin has also served on the Boards of Cambridge Innovation Capital and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, on the Innovation Board and Medical Expert Network of the Association of the British Pharmaceutical Industry, on a Department of Health Multi-centre Research Ethics Committee, on the Emerging Science and Bioethics Advisory Committee of the Dept. of Health, and the Board of Governors of Heathfield School for Girls (The Girls’ Day School Trust).
“Lineage’s clinical-stage programs and platform technologies have the potential to transform outcomes for patients suffering from serious medical conditions,” said Dr. Amin. “I am excited about the opportunity to contribute to the Company’s future growth. I particularly look forward to helping guide the advancement of Lineage’s novel cell therapy product candidates toward later-stage clinical trials and the execution of other potentially valuable development activities, with an ultimate focus on transforming the lives of patients and creating value for the Company’s shareholders.”
Dr. Amin received her MB, BS (Bachelor of Medicine; Bachelor of Surgery) from Guys Hospital and St Thomas’ Hospitals (now GKT) Medical School in 1987. She holds the following certifications: DRCOG (Diploma of the Royal College of Obstetrics & Gynaecologists), DGM (Diploma in Geriatric Medicine of the Royal College of Physicians), MRCGP (Member of the Royal College of General Practitioners), DCH (Diploma in Child Health of the Royal College of Physicians), DCPSA (Diploma in Clinical Pharmacology), MFPM (Awarded Membership by Distinction of the Faculty of Pharmaceutical Medicine) and FFPM (Fellow of the Faculty of Pharmaceutical Medicine). Her clinical research work has been widely published in professional journals and textbooks, and she is a recognized presenter at international conferences.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer.
For more information: https://lineagecell.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.